Atara Biotherapeutics Announces Positive Results from Pivotal Phase 3 Trial (ALLELE) of Tab-cel at the 63rd American Society of Hematology (ASH) Annual Meeting

14.12.2021 - Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today ... Seite 1

Related Keywords

United States ,American ,Jakob Dupont ,Atara Biotherapeutics Inc ,American Society Of Hematology ,Head Of Global Research Development At Atara ,Nasdaq ,Expanded Access Protocol ,American Society ,Global Research ,Atara Biotherapeutics ,